RVMD Revolution Medicines, Inc. Stock Quote

RVMD [NASD]

Index	-	P/E	-	EPS (ttm)	-1.77	Insider Own	0.60%	Shs Outstand	66.40M	Perf Week	0.25%
Market Cap	2.80B	Forward P/E	-	EPS next Y	-2.60	Insider Trans	-90.95%	Shs Float	55.21M	Perf Month	-15.32%
Income	-110.40M	PEG	-	EPS next Q	-0.52	Inst Own	78.80%	Short Float	11.26%	Perf Quarter	-3.48%
Sales	43.00M	P/S	65.11	EPS this Y	-91.70%	Inst Trans	1.39%	Short Ratio	10.58	Perf Half Y	-11.97%
Book/sh	7.15	P/B	5.50	EPS next Y	-11.60%	ROA	-21.30%	Target Price	54.00	Perf Year	71.09%
Cash/sh	6.20	P/C	6.35	EPS next 5Y	-	ROE	-25.60%	52W Range	21.17 - 56.18	Perf YTD	-0.61%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-23.20%	52W High	-29.96%	Beta	-
Dividend %	-	Quick Ratio	9.60	Sales past 5Y	-	Gross Margin	-	52W Low	85.88%	ATR	2.76
Employees	125	Current Ratio	9.60	Sales Q/Q	-27.30%	Oper. Margin	-	RSI (14)	39.88	Volatility	7.01% 6.70%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-61.30%	Profit Margin	-	Rel Volume	0.63	Prev Close	40.32
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	587.16K	Price	39.35
Recom	1.80	SMA20	-10.69%	SMA50	-14.39%	SMA200	4.81%	Volume	369,432	Change	-2.41%

May-21-20

Initiated

H.C. Wainwright

Buy

$55

Mar-09-20

Initiated

JP Morgan

Neutral

$32

Mar-09-20

Initiated

Guggenheim

Buy

$50

Mar-09-20

Initiated

Cowen

Outperform

Apr-12-21 08:43AM	Does Revolution Medicines' (NASDAQ:RVMD) Share Price Gain of 80% Match Its Business Performance? Simply Wall St. -8.01%
Apr-02-21 06:15AM	This 2020 Biotech IPO Is Poised to Break Out in 2021 Motley Fool
Mar-11-21 04:05PM	Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021 GlobeNewswire
Mar-09-21 07:30AM	Revolution Medicines to Participate in Upcoming Investor Conferences GlobeNewswire +5.92%
Mar-02-21 04:05PM	Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress GlobeNewswire
Feb-18-21 07:30AM	Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences GlobeNewswire -5.05%
Feb-09-21 07:43AM	Estimating The Fair Value Of Revolution Medicines, Inc. (NASDAQ:RVMD) Simply Wall St.
Feb-08-21 04:01PM	Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares GlobeNewswire
Feb-04-21 07:54AM	Revolution Medicines Raises $260.9 Million In Upsized Offering Benzinga +5.39%
Feb-03-21 11:30PM	Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock GlobeNewswire
Feb-01-21 04:01PM	Revolution Medicines Announces Proposed Public Offering of Common Stock GlobeNewswire +6.31%
Jan-05-21 07:30AM	Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-15-20 10:16PM	Is RVMD A Good Stock To Buy Now? Insider Monkey
Nov-26-20 02:41AM	We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth Simply Wall St.
Nov-12-20 07:30AM	Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress GlobeNewswire +6.38%
Oct-24-20 09:45AM	Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers GlobeNewswire
06:00AM	Cancer Meeting Could Ignite These Biotech Stocks Barrons.com
Oct-12-20 07:30AM	Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors GlobeNewswire
Sep-22-20 08:52AM	Revolution Medicines (RVMD) Looks Good: Stock Adds 6.9% in Session Zacks
Sep-18-20 04:16PM	High Hopes for Amgen and Gilead at Europes Biggest Cancer Research Conference Barrons.com
Sep-16-20 09:00AM	Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors GlobeNewswire
Sep-09-20 07:30AM	Revolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire +5.69%
Sep-08-20 07:30AM	Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference GlobeNewswire
Aug-28-20 11:12AM	Here's What Revolution Medicines, Inc.'s (NASDAQ:RVMD) Shareholder Ownership Structure Looks Like Simply Wall St.
Aug-10-20 07:30AM	Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress GlobeNewswire +8.70%
Jul-13-20 04:01PM	Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares GlobeNewswire -8.17%
08:53AM	Revolution Medicines (RVMD) Catches Eye: Stock Jumps 10.2% Zacks
Jul-06-20 04:01PM	Revolution Medicines Announces Proposed Public Offering of Common Stock GlobeNewswire
Jun-30-20 04:05PM	Revolution Medicines Reports New Application of Tri-Complex Modality for Undruggable Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel Coronavirus GlobeNewswire
Jun-22-20 04:01PM	Revolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer Therapies GlobeNewswire
07:30AM	Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor GlobeNewswire
Jun-18-20 07:30AM	Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors GlobeNewswire
Jun-09-20 07:30AM	Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510 GlobeNewswire
May-22-20 10:29PM	Why Blackstone Stock Looks Attractive Barrons.com -7.22%
May-19-20 07:30AM	Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II GlobeNewswire -6.58%
May-14-20 04:05PM	Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress GlobeNewswire
Apr-29-20 08:05AM	Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models GlobeNewswire +8.66%
Mar-18-20 07:30AM	Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program GlobeNewswire
Mar-09-20 07:30AM	New Clinical Trial Exploring Revolution Medicines Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute GlobeNewswire
Feb-18-20 04:01PM	Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Feb-14-20 01:24PM	The Funded: 7 Bay Area startups raise over $135M at week's end American City Business Journals
Feb-13-20 11:20AM	Revolution Medicines shares soar 85% in trading debut after IPO priced at top end of range MarketWatch
Feb-12-20 07:56PM	Revolution Medicines prices IPO at $17 a share MarketWatch
07:39PM	Revolution Medicines Announces Pricing of Initial Public Offering GlobeNewswire
Feb-11-20 07:12AM	Revolution Medicines increases size of planned IPO and raises price range MarketWatch

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Svennilson Peter	Director	Apr 09	Sale	43.83	24,701	1,082,541	1,607,848	Apr 12 05:41 PM
Svennilson Peter	Director	Apr 08	Sale	44.80	46,228	2,071,204	1,619,448	Apr 12 05:41 PM
Svennilson Peter	Director	Apr 07	Sale	45.60	27,953	1,274,783	1,641,158	Apr 07 06:23 PM
Svennilson Peter	Director	Apr 06	Sale	48.06	39,500	1,898,441	1,654,286	Apr 07 06:23 PM
Svennilson Peter	Director	Apr 05	Sale	46.65	18,215	849,817	1,672,837	Apr 07 06:23 PM
Miller Vincent A.	Director	Mar 22	Option Exercise	4.73	3,200	15,136	23,333	Mar 24 06:11 PM
Miller Vincent A.	Director	Mar 22	Sale	49.00	3,200	156,800	20,133	Mar 24 06:11 PM
GOLDSMITH MARK A	See Remarks	Mar 01	Option Exercise	1.12	5,000	5,600	5,744	Mar 03 06:06 PM
GOLDSMITH MARK A	See Remarks	Mar 01	Sale	46.00	5,000	229,981	744	Mar 03 06:06 PM
Horn Margaret A	See Remarks	Feb 05	Option Exercise	4.73	35,000	165,550	46,198	Feb 08 07:06 PM
GOLDSMITH MARK A	See Remarks	Feb 05	Option Exercise	1.12	15,000	16,800	15,744	Feb 08 07:06 PM
Horn Margaret A	See Remarks	Feb 05	Sale	55.00	35,000	1,925,000	11,198	Feb 08 07:06 PM
GOLDSMITH MARK A	See Remarks	Feb 05	Sale	55.00	15,000	825,000	744	Feb 08 07:06 PM
Weber Barbara	Director	Feb 04	Option Exercise	4.73	5,000	23,650	6,808	Feb 05 08:09 PM
Weber Barbara	Director	Feb 04	Sale	50.35	5,000	251,767	1,808	Feb 05 08:09 PM
Weber Barbara	Director	Feb 02	Option Exercise	1.12	5,336	5,976	7,144	Feb 03 09:00 AM
GOLDSMITH MARK A	See Remarks	Feb 02	Option Exercise	1.12	5,000	5,600	5,744	Feb 03 09:01 AM
Weber Barbara	Director	Feb 02	Sale	45.00	5,336	240,120	1,808	Feb 03 09:00 AM
GOLDSMITH MARK A	See Remarks	Feb 02	Sale	45.42	5,000	227,101	744	Feb 03 09:01 AM
Weber Barbara	Director	Dec 30	Option Exercise	1.12	5,336	5,976	7,144	Jan 04 07:50 PM
Weber Barbara	Director	Dec 30	Sale	40.95	5,336	218,530	1,808	Jan 04 07:50 PM
COLUMN GROUP III, LP	10% Owner	Nov 16	Sale	36.40	1,075,133	39,134,841	2,429,180	Nov 18 07:06 PM
COLUMN GROUP III, LP	10% Owner	Nov 16	Sale	36.40	952,023	34,653,637	2,151,026	Nov 18 07:06 PM
Svennilson Peter	Director	Nov 16	Sale	36.40	2,027,156	73,788,478	2,151,026	Nov 18 06:58 PM
ANDERSON ELIZABETH M	Director	Oct 15	Sale	45.00	4,780	215,100	26,990	Oct 15 07:15 PM
Anders Jack	See Remarks	Oct 13	Option Exercise	2.68	10,000	26,800	10,000	Oct 15 07:14 PM
ANDERSON ELIZABETH M	Director	Oct 13	Sale	45.00	220	9,900	31,770	Oct 15 07:15 PM
Anders Jack	See Remarks	Oct 13	Sale	44.00	10,000	440,000	0	Oct 15 07:14 PM
Anders Jack	See Remarks	Oct 06	Option Exercise	2.68	10,000	26,800	10,000	Oct 08 05:07 PM
Anders Jack	See Remarks	Oct 06	Sale	40.00	10,000	400,000	0	Oct 08 05:07 PM
Miller Vincent A.	Director	Oct 06	Sale	39.00	6,250	243,750	20,133	Oct 08 05:07 PM
ANDERSON ELIZABETH M	Director	Oct 06	Sale	40.00	5,000	200,000	31,990	Oct 08 05:06 PM
Weber Barbara	Director	Oct 05	Option Exercise	1.12	7,196	8,060	9,004	Oct 05 08:17 PM
Weber Barbara	Director	Oct 05	Sale	36.17	7,196	260,313	1,808	Oct 05 08:17 PM
Weber Barbara	Director	Oct 02	Option Exercise	1.12	804	900	2,612	Oct 05 08:17 PM
Horn Margaret A	See Remarks	Oct 02	Sale	35.40	12,495	442,321	53,302	Oct 02 07:01 PM
Weber Barbara	Director	Oct 02	Sale	36.02	804	28,960	1,808	Oct 05 08:17 PM
Weber Barbara	Director	Oct 01	Option Exercise	1.12	2,000	2,240	3,808	Oct 05 08:17 PM
Horn Margaret A	See Remarks	Oct 01	Sale	35.01	57,505	2,013,170	65,797	Oct 02 07:01 PM
Weber Barbara	Director	Oct 01	Sale	34.76	2,000	69,521	1,808	Oct 05 08:17 PM
Kelsey Stephen Michael	See Remarks	Sep 30	Option Exercise	4.73	17,248	81,583	253,577	Sep 30 08:31 PM
GOLDSMITH MARK A	See Remarks	Sep 30	Option Exercise	4.73	42,578	201,286	42,578	Sep 30 08:32 PM
GOLDSMITH MARK A	See Remarks	Sep 30	Sale	34.12	1,312	44,762	71,879	Sep 30 08:32 PM
GOLDSMITH MARK A	See Remarks	Sep 30	Sale	34.40	42,578	1,464,854	0	Sep 30 08:32 PM
Kelsey Stephen Michael	See Remarks	Sep 30	Sale	34.33	17,248	592,060	236,329	Sep 30 08:31 PM
Kelsey Stephen Michael	See Remarks	Sep 29	Option Exercise	4.73	13,268	62,758	249,597	Sep 30 08:31 PM
GOLDSMITH MARK A	See Remarks	Sep 29	Option Exercise	4.51	30,523	137,688	30,523	Sep 30 08:32 PM
Miller Vincent A.	Director	Sep 29	Sale	34.07	450	15,332	26,383	Sep 30 08:33 PM
Kelsey Stephen Michael	See Remarks	Sep 29	Sale	34.14	13,268	452,914	236,329	Sep 30 08:31 PM
GOLDSMITH MARK A	See Remarks	Sep 29	Sale	34.08	21,088	718,652	73,191	Sep 30 08:32 PM
GOLDSMITH MARK A	See Remarks	Sep 29	Sale	34.14	30,523	1,041,918	0	Sep 30 08:32 PM
GOLDSMITH MARK A	See Remarks	Sep 28	Option Exercise	4.09	10,132	41,440	10,132	Sep 30 08:32 PM
Kelsey Stephen Michael	See Remarks	Sep 28	Option Exercise	4.73	9,384	44,386	245,713	Sep 30 08:31 PM
GOLDSMITH MARK A	See Remarks	Sep 28	Sale	34.08	7,500	255,605	94,279	Sep 30 08:32 PM
GOLDSMITH MARK A	See Remarks	Sep 28	Sale	34.11	10,132	345,567	0	Sep 30 08:32 PM
Miller Vincent A.	Director	Sep 28	Sale	34.11	5,300	180,772	26,833	Sep 30 08:33 PM
Kelsey Stephen Michael	See Remarks	Sep 28	Sale	34.08	9,384	319,831	236,329	Sep 30 08:31 PM
GOLDSMITH MARK A	See Remarks	Sep 23	Option Exercise	4.09	100	409	100	Sep 23 08:36 PM
Kelsey Stephen Michael	See Remarks	Sep 23	Option Exercise	4.73	100	473	236,429	Sep 23 08:35 PM
Kelsey Stephen Michael	See Remarks	Sep 23	Sale	34.02	100	3,402	236,329	Sep 23 08:35 PM
GOLDSMITH MARK A	See Remarks	Sep 23	Sale	34.02	100	3,402	101,779	Sep 23 08:36 PM
GOLDSMITH MARK A	See Remarks	Sep 23	Sale	34.01	100	3,401	0	Sep 23 08:36 PM
Miller Vincent A.	Director	Sep 23	Sale	34.02	500	17,010	32,133	Sep 25 04:29 PM
GOLDSMITH MARK A	See Remarks	Sep 22	Option Exercise	4.09	10,097	41,297	10,097	Sep 23 08:36 PM
Kelsey Stephen Michael	See Remarks	Sep 22	Sale	33.00	98	3,234	236,329	Sep 23 08:35 PM
GOLDSMITH MARK A	See Remarks	Sep 22	Sale	33.00	541	17,853	101,879	Sep 23 08:36 PM
GOLDSMITH MARK A	See Remarks	Sep 22	Sale	33.15	10,097	334,713	0	Sep 23 08:36 PM
GOLDSMITH MARK A	See Remarks	Sep 21	Option Exercise	4.09	29,903	122,303	29,903	Sep 23 08:36 PM
GOLDSMITH MARK A	See Remarks	Sep 21	Sale	33.00	11,459	378,173	102,420	Sep 23 08:36 PM
GOLDSMITH MARK A	See Remarks	Sep 21	Sale	33.00	29,903	986,850	0	Sep 23 08:36 PM
Kelsey Stephen Michael	See Remarks	Sep 21	Sale	33.00	14,902	491,805	236,427	Sep 23 08:35 PM
GOLDSMITH MARK A	See Remarks	Sep 18	Option Exercise	3.57	7,342	26,209	7,342	Sep 18 08:01 PM
GOLDSMITH MARK A	See Remarks	Sep 18	Sale	31.05	712	22,106	113,879	Sep 18 08:01 PM
GOLDSMITH MARK A	See Remarks	Sep 18	Sale	31.67	7,342	232,521	0	Sep 18 08:01 PM
Kelsey Stephen Michael	See Remarks	Sep 18	Sale	31.03	637	19,767	251,329	Sep 18 08:00 PM
GOLDSMITH MARK A	See Remarks	Sep 17	Option Exercise	1.12	27,363	30,647	27,363	Sep 18 08:01 PM
GOLDSMITH MARK A	See Remarks	Sep 17	Sale	31.03	11,288	350,311	114,591	Sep 18 08:01 PM
GOLDSMITH MARK A	See Remarks	Sep 17	Sale	30.82	27,363	843,221	0	Sep 18 08:01 PM
Kelsey Stephen Michael	See Remarks	Sep 17	Sale	31.03	11,363	352,556	251,966	Sep 18 08:00 PM
GOLDSMITH MARK A	See Remarks	Sep 16	Option Exercise	1.12	8,813	9,871	8,813	Sep 18 08:01 PM
GOLDSMITH MARK A	See Remarks	Sep 16	Sale	29.04	8,813	255,956	0	Sep 18 08:01 PM
GOLDSMITH MARK A	See Remarks	Sep 10	Option Exercise	1.12	2,544	2,849	2,544	Sep 11 06:35 PM
Kelsey Stephen Michael	See Remarks	Sep 10	Option Exercise	4.73	1,002	4,739	265,871	Sep 10 09:30 PM
GOLDSMITH MARK A	See Remarks	Sep 10	Sale	29.00	4,399	127,571	125,879	Sep 11 06:35 PM
GOLDSMITH MARK A	See Remarks	Sep 10	Sale	29.07	2,544	73,948	0	Sep 11 06:35 PM
Kelsey Stephen Michael	See Remarks	Sep 10	Sale	29.06	2,542	73,880	263,329	Sep 10 09:30 PM
GOLDSMITH MARK A	See Remarks	Sep 09	Sale	29.00	100	2,900	130,251	Sep 11 06:35 PM
Kelsey Stephen Michael	See Remarks	Sep 09	Sale	29.04	100	2,904	264,869	Sep 10 09:30 PM
Kelsey Stephen Michael	See Remarks	Sep 08	Option Exercise	4.73	600	2,838	266,369	Sep 10 09:30 PM
GOLDSMITH MARK A	See Remarks	Sep 08	Option Exercise	1.12	900	1,008	900	Sep 10 09:31 PM
Kelsey Stephen Michael	See Remarks	Sep 08	Sale	29.06	1,400	40,683	264,969	Sep 10 09:30 PM
GOLDSMITH MARK A	See Remarks	Sep 08	Sale	29.05	900	26,145	0	Sep 10 09:31 PM
GOLDSMITH MARK A	See Remarks	Sep 08	Sale	29.05	900	26,141	130,351	Sep 10 09:31 PM
GOLDSMITH MARK A	See Remarks	Sep 03	Option Exercise	1.12	500	560	500	Sep 04 07:05 PM
Kelsey Stephen Michael	See Remarks	Sep 03	Option Exercise	4.73	700	3,311	267,169	Sep 03 07:55 PM
GOLDSMITH MARK A	See Remarks	Sep 03	Sale	29.07	700	20,352	131,251	Sep 04 07:05 PM
GOLDSMITH MARK A	See Remarks	Sep 03	Sale	29.07	500	14,533	0	Sep 04 07:05 PM
Kelsey Stephen Michael	See Remarks	Sep 03	Sale	29.07	1,400	40,699	265,769	Sep 03 07:55 PM
GOLDSMITH MARK A	See Remarks	Sep 02	Option Exercise	1.12	1,100	1,232	1,100	Sep 04 07:05 PM
Kelsey Stephen Michael	See Remarks	Sep 02	Option Exercise	4.73	100	473	267,295	Sep 03 07:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience